{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreienbkhpl6kmykf3fnx6q7ftxc4tva7c56fbms5qh7ner6lxvqn5du",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mldsuxie6dr2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihgb5tpicua6glkjxziq26dz4rgpppq46tjc2jeud62p4zesrsbpq"
    },
    "mimeType": "image/jpeg",
    "size": 319316
  },
  "path": "/news/2026-05-technology-fda-breast-cancer-treatment.html",
  "publishedAt": "2026-05-08T08:40:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause them.",
  "title": "Technology receives FDA approval for breast cancer treatment"
}